Considering the role of IL-6 in the pathogenesis of colitis and the promotion of tumor progress and metastasis, tocilizumab, an anti-IL-6 receptor antibody, has been investigated as an alternative in the management of ICI colitis.113 Interleukin-6 inhibition could obtain both tumor suppression and control of the side effects of therapy. This evidence concerns the gene IL6 and colitis.